Reactivation of hepatitis B after liver transplantation

Current knowledge, molecular mechanisms and implications in management

Ranjit Chauhan, Shilpa Lingala, Chiranjeevi Gadiparthi, Nivedita Lahiri, Smruti R. Mohanty, Jian Wu, Tomasz I. Michalak, Sanjaya Satapathy

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Chronic hepatitis B (CHB) is a major global health problem affecting an estimated 350 million people with more than 786000 individuals dying annually due to complications, such as cirrhosis, liver failure and hepatocellular carcinoma (HCC). Liver transplantation (LT) is considered gold standard for treatment of hepatitis B virus (HBV)-related liver failure and HCC. However, post-transplant viral reactivation can be detrimental to allograft function, leading to poor survival. Prophylaxis with high-dose hepatitis B immunoglobulin (HBIG) and anti-viral drugs have achieved remarkable progress in LT by suppressing viral replication and improving long-term survival. The combination of lamivudine (LAM) plus HBIG has been for many years the most widely used. However, life-long HBIG use is both cumbersome and costly, whereas long-term use of LAM results in resistant virus. Recently, in an effort to develop HBIG-free protocols, high potency nucleos(t)ide analogues, such as Entecavir or Tenofovir, have been tried either as monotherapy or in combination with low-dose HBIG with excellent results. Current focus is on novel antiviral targets, especially for covalently closed circular DNA (cccDNA), in an effort to eradicate HBV infection instead of viral suppression. However, there are several other molecular mechanisms through which HBV may reactivate and need equal attention. The purpose of this review is to address post-LT HBV reactivation, its risk factors, underlying molecular mechanisms, and recent advancements and future of anti-viral therapy.

Original languageEnglish (US)
Pages (from-to)352-370
Number of pages19
JournalWorld Journal of Hepatology
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Hepatitis B
Liver Transplantation
Immunoglobulins
Hepatitis B virus
Lamivudine
Tenofovir
Liver Failure
Hepatocellular Carcinoma
Circular DNA
Chronic Hepatitis B
Virus Diseases
Antiviral Agents
Allografts
Fibrosis
Viruses
Transplants
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Reactivation of hepatitis B after liver transplantation : Current knowledge, molecular mechanisms and implications in management. / Chauhan, Ranjit; Lingala, Shilpa; Gadiparthi, Chiranjeevi; Lahiri, Nivedita; Mohanty, Smruti R.; Wu, Jian; Michalak, Tomasz I.; Satapathy, Sanjaya.

In: World Journal of Hepatology, Vol. 10, No. 3, 01.01.2018, p. 352-370.

Research output: Contribution to journalReview article

Chauhan, Ranjit ; Lingala, Shilpa ; Gadiparthi, Chiranjeevi ; Lahiri, Nivedita ; Mohanty, Smruti R. ; Wu, Jian ; Michalak, Tomasz I. ; Satapathy, Sanjaya. / Reactivation of hepatitis B after liver transplantation : Current knowledge, molecular mechanisms and implications in management. In: World Journal of Hepatology. 2018 ; Vol. 10, No. 3. pp. 352-370.
@article{6f3f525cc2ee45ca900aad8646295be4,
title = "Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management",
abstract = "Chronic hepatitis B (CHB) is a major global health problem affecting an estimated 350 million people with more than 786000 individuals dying annually due to complications, such as cirrhosis, liver failure and hepatocellular carcinoma (HCC). Liver transplantation (LT) is considered gold standard for treatment of hepatitis B virus (HBV)-related liver failure and HCC. However, post-transplant viral reactivation can be detrimental to allograft function, leading to poor survival. Prophylaxis with high-dose hepatitis B immunoglobulin (HBIG) and anti-viral drugs have achieved remarkable progress in LT by suppressing viral replication and improving long-term survival. The combination of lamivudine (LAM) plus HBIG has been for many years the most widely used. However, life-long HBIG use is both cumbersome and costly, whereas long-term use of LAM results in resistant virus. Recently, in an effort to develop HBIG-free protocols, high potency nucleos(t)ide analogues, such as Entecavir or Tenofovir, have been tried either as monotherapy or in combination with low-dose HBIG with excellent results. Current focus is on novel antiviral targets, especially for covalently closed circular DNA (cccDNA), in an effort to eradicate HBV infection instead of viral suppression. However, there are several other molecular mechanisms through which HBV may reactivate and need equal attention. The purpose of this review is to address post-LT HBV reactivation, its risk factors, underlying molecular mechanisms, and recent advancements and future of anti-viral therapy.",
author = "Ranjit Chauhan and Shilpa Lingala and Chiranjeevi Gadiparthi and Nivedita Lahiri and Mohanty, {Smruti R.} and Jian Wu and Michalak, {Tomasz I.} and Sanjaya Satapathy",
year = "2018",
month = "1",
day = "1",
doi = "10.4254/wjh.v10.i3.352",
language = "English (US)",
volume = "10",
pages = "352--370",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "3",

}

TY - JOUR

T1 - Reactivation of hepatitis B after liver transplantation

T2 - Current knowledge, molecular mechanisms and implications in management

AU - Chauhan, Ranjit

AU - Lingala, Shilpa

AU - Gadiparthi, Chiranjeevi

AU - Lahiri, Nivedita

AU - Mohanty, Smruti R.

AU - Wu, Jian

AU - Michalak, Tomasz I.

AU - Satapathy, Sanjaya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chronic hepatitis B (CHB) is a major global health problem affecting an estimated 350 million people with more than 786000 individuals dying annually due to complications, such as cirrhosis, liver failure and hepatocellular carcinoma (HCC). Liver transplantation (LT) is considered gold standard for treatment of hepatitis B virus (HBV)-related liver failure and HCC. However, post-transplant viral reactivation can be detrimental to allograft function, leading to poor survival. Prophylaxis with high-dose hepatitis B immunoglobulin (HBIG) and anti-viral drugs have achieved remarkable progress in LT by suppressing viral replication and improving long-term survival. The combination of lamivudine (LAM) plus HBIG has been for many years the most widely used. However, life-long HBIG use is both cumbersome and costly, whereas long-term use of LAM results in resistant virus. Recently, in an effort to develop HBIG-free protocols, high potency nucleos(t)ide analogues, such as Entecavir or Tenofovir, have been tried either as monotherapy or in combination with low-dose HBIG with excellent results. Current focus is on novel antiviral targets, especially for covalently closed circular DNA (cccDNA), in an effort to eradicate HBV infection instead of viral suppression. However, there are several other molecular mechanisms through which HBV may reactivate and need equal attention. The purpose of this review is to address post-LT HBV reactivation, its risk factors, underlying molecular mechanisms, and recent advancements and future of anti-viral therapy.

AB - Chronic hepatitis B (CHB) is a major global health problem affecting an estimated 350 million people with more than 786000 individuals dying annually due to complications, such as cirrhosis, liver failure and hepatocellular carcinoma (HCC). Liver transplantation (LT) is considered gold standard for treatment of hepatitis B virus (HBV)-related liver failure and HCC. However, post-transplant viral reactivation can be detrimental to allograft function, leading to poor survival. Prophylaxis with high-dose hepatitis B immunoglobulin (HBIG) and anti-viral drugs have achieved remarkable progress in LT by suppressing viral replication and improving long-term survival. The combination of lamivudine (LAM) plus HBIG has been for many years the most widely used. However, life-long HBIG use is both cumbersome and costly, whereas long-term use of LAM results in resistant virus. Recently, in an effort to develop HBIG-free protocols, high potency nucleos(t)ide analogues, such as Entecavir or Tenofovir, have been tried either as monotherapy or in combination with low-dose HBIG with excellent results. Current focus is on novel antiviral targets, especially for covalently closed circular DNA (cccDNA), in an effort to eradicate HBV infection instead of viral suppression. However, there are several other molecular mechanisms through which HBV may reactivate and need equal attention. The purpose of this review is to address post-LT HBV reactivation, its risk factors, underlying molecular mechanisms, and recent advancements and future of anti-viral therapy.

UR - http://www.scopus.com/inward/record.url?scp=85044679286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044679286&partnerID=8YFLogxK

U2 - 10.4254/wjh.v10.i3.352

DO - 10.4254/wjh.v10.i3.352

M3 - Review article

VL - 10

SP - 352

EP - 370

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 3

ER -